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Abstract. It is well recognized that arsenic trioxide (ATO) is an efficacious agent
of acute promyelocytic leukemia (APL). Use of single agent ATO in the treatment of APL leads to 
remissions which are durable in the majority. ATO is probably the most effective single agent in the 
treatment of APL and there have been ver
both as a single agent and in combination with other conventional drugs to treat APL. Use of ATO 
is the accepted standard of care in the management of relapsed APL, where it is often used 
effectively as a bridge to a stem cell transplant. However, its role in newly diagnosed APL remains 
controversial. ATO probably has multiple mechanisms of action. Better understanding of its 
mechanisms of action/s is likely to lead to more rationale use of this agent or
alone or in combination with other drugs. There is limited data on the kinetics of leukemia 
clearance and normal haematopoietic recovery after the administration of single agent ATO for the 
treatment of APL, preliminary data suggest
therapy. There have been a number of concerns of the potential short and long term toxicity of this 
agent. Most such concerns arise from the toxicity profile noted in people exposed to long term 
arsenic exposure in the environment. With the therapeutic doses and schedules of administration of 
ATO in the treatment of malignancies the overall toxicity profile has been favorable. In a resource 
constrained environments the use of a single agent ATO based reg
option to treat almost all patients. In the developed world it has the potential in combination with 
other agents to improve the clinical outcome with reduction of dose intensity of chemotherapy and 
remains an option for patients who would not tolerate conventional therapy. In this review we focus 
on the use of single agent ATO for the treatment of APL and summarize our experience and review 
the literature.
Introduction. Arsenical compounds were used as early 
as 2000 BC, both as a medicine and as a poison
use of these compounds as medicines was familiar to 
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y few reports of primary resistance. It has been used 
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1. The 
the early physicians such as Hippocrates (460 
BC), Aristotle (384 – 322 BC) and Pliny the Elder (23 
– 79 AD). It was Paracelsus (1493 
for the treatment 
its derivatives either 
– 377 
– 1541 AD) who 
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used arsenicals extensively and was quoted as saying 
“All substances are poisons; the right dose 
differentiates a poison from a remedy”.1 In the 
eighteenth century, Fowlers solution (1% potassium 
arsenite) was very popular and was used in the 
treatment of various ailments, predominantly for 
dermatological conditions.1
Historically the prominence of arsenic trioxide 
(ATO) in the treatment of acute promyelocytic 
leukemia (APL) followed the observation of Chinese 
investigators at Harbin Medical University who 
systematically studied the role of arsenic based 
traditional Chinese recipe called ‘Ailing I,’ that had 
been reported to be useful in the treatment of various 
malignancies.  They labeled this native preparation 713 
(for the year and month that the study was initiated) 
and studied it more than a 1000 patients with various 
malignancies2. They soon noted that this agent worked 
best in the treatment of patients with APL. Two 
subsequent Chinese studies confirmed the benefit of 
this agent in APL.3,4
Since then there have been numerous reports on the 
use of ATO in the treatment of relapsed and newly 
diagnosed cases of APL. In this review we focus 
mainly on the treatment of APL with single agent 
ATO. We review our centers experience from 1998 and 
attempt to put this into context of current international 
management strategies, experience from other centers 
and address the socio-economic relevance of this 
strategy. We also attempt to highlight the significant 
differences in this approach compared to that when 
chemotherapeutic agents are used up front. Very 
briefly we also address the mechanism of action of this 
agent, the pharmacokinetic data and toxicity profile 
which we feel is critical to this discussion.   
Mechanism of Action of Arsenic Trioxide. The 
mechanism by which ATO induces remission in APL 
is still under evaluation. Table 1 summarizes the 
postulated mechanisms by which ATO mediates its 
anti-leukemia effect. While some aspects of its cellular 
effects are clear, the molecular basis, for these protean 
effects are not fully defined. Initial in-vitro studies 
suggested that it induces apoptosis in APL (NB4) cell 
lines by down regulation of Bcl-2.5 However, the 
clinical observation that a leucocytic response followed 
the administration of ATO consistently in the majority 
of patients, was suggestive of a differentiating process, 
as seen following the use of all-trans retinoic acid 
(ATRA). It was subsequently reported that in fact a 
dual effect of ATO was seen on promyelocytic cell 
lines, at low doses (0.1 – 0.5  umol/lt) there was partial 
differentiation and at higher doses there was 
preferential apoptosis (0.5 – 2 umol/lt).6 This has been 
subsequently demonstrated by a number of other
Table 1. Mechanism of action of arsenic trioxide.
I] Induce apoptosis
(0.5-1.0µM)
II] Induce differentiation
( <0.5µM)
-downregulation of bcl25 -degradation of PML-RARα57
-increased expression of 
caspases58
- methylation of histones59
-activation of jun kinases60
-reorganize PML oncogenic 
domain (POD)61,62
-disruption of cytoskeleton63
-inhibition of NFkB64,65
III] Altered cellular Redox 
status
IV] Inhibits angiogenesis
-reactive oxygen species (ROS) 
generation67,68
-down regulates VEGF66
-bind sulfhydryl rich 
proteins/enzymes such as 
glutathione and reduce there 
levels69 
groups independently.7,8The differentiation with ATO 
is incomplete and usually proceeds only till the 
myelocyte stage following which it appears that 
apoptosis is the predominant mode of action.6 More 
recently data suggests that ATO but not ATRA can 
eliminate the leukemia initiating compartment in 
APL.9,10 This could partly explain why ATO but not 
ATRA, as single agent, is able to induce durable 
remission in the clinic.
Pharmacokinetics, Pharmacogenomics, Dose and 
Schedule of Arsenic Trioxide. The lethal dose 
recorded in the literature is a single dose of more than 
100mg11. The dose of arsenic trioxide in the initial 
published study by Zhi-Xiang et al11 was 10 mg a day 
for adults till complete hematological remission (CR) 
was achieved. Subsequently a break of 30 days was 
given and a second course of 28 days administered. It 
is important to recognize that this dosing was based on 
there earlier experience with doses used in native 
Chinese medicine and not on phase I clinical trials 
addressing dose limiting toxicity. The study reported 
by Soignet et al12 used a similar dose for adults but 
used a dose of 0.15 mg/kg/day for children. From there 
experience they noted that ATO is active in APL from 
0.06mg/kg to 0.2 mg/kg. Within this range they did not 
find any difference in efficacy. Subsequent studies 
have used similar dosages of ATO. Pharmacokinetic 
studies done at this dosage demonstrated that mean 
peak plasma levels of 6.85 micro moles / Lt (range: 
5.54 – 7.30) was achieved. The plasma half life was 
12.13±3.31 hours. Importantly these parameters did not 
change with continuous administration.11 Reports of 
daily urinary excretion in the literature varies from 
between 1 – 8% to 32-65% of the daily dose 
administered and more importantly is continued even 
after the drug administration had been stopped.11,13
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patients on dialysis.14 While the cumulative level of 
arsenic increases in the body (as demonstrated in hair 
and nail analysis) with continuous administration, the 
urinary excretion continues even after the ATO 
administration has stopped leading to a gradual 
decrease in the cumulative amount of arsenic trioxide 
in the body. In our own experience there was no 
significant difference in the ATO content from patients 
and normal controls hair and nail samples on long term 
follow up.15 This was the rationale for giving 4 week 
breaks between the courses of ATO in the regimen 
used by us,16 the breaks were intended to reduce the 
cumulative dose significantly. 
This pattern of ATO exposure is very different from 
that seen with environmental toxicity where there is a 
slow but constant accumulation of arsenic which leads 
to a toxicity profile that is very different from that seen 
when ATO is used in therapy at currently 
recommended doses and schedules. Extrapolating and 
anticipating the toxicity profile seen with chronic 
environmental exposure to the potential toxicity with 
currently used dosage schedules of ATO is unfair, 
unwarranted and without any scientific basis. In the 
absence of a dose defining phase I clinical trial there is 
insufficient data on the upper limit of a safe therapeutic 
dose. It is of interest to note that in our initial cohort we 
noted a decreased risk of relapse among patient who 
had hepatotoxicity Vs. those that did not following 
treatment with ATO17 (Figure 1). This would suggest 
that there is either a significant inter-individual 
variation in biotransformation of this agent and as a 
result some patients were receiving less than an 
optimal dose or that there were yet unknown variables 
that resulted in this association.17 There is a need to 
revisit what is the optimal dose of ATO to treat APL in 
a large clinical trial. There is very limited data on the 
optimal duration of administration of ATO as a single 
agent in the management of ATO. Based on the general 
consensus that maintenance was required in the 
management of APL we arbitrarily opted for a 6 
months duration of maintenance.16 Recently published 
data from Iran suggests that 4 courses of ATO was 
significantly better than 2.18 We subsequently 
undertook a larger multi-center study and randomized 
patients with the same induction and consolidation into 
a 6 and a 12 month maintenance regimen and did not 
find a significant benefit from increasing the duration 
of maintenance (unpublished data, to be presented at 
ASH 2011). Zhou et al reported treating children with 
ATO for prolonged periods of up to 3 years with very 
good efficacy and without significantly increasing the 
toxicity.19   
It has been noted that there is considerable inter 
Figure 1. Five year Kaplan-Meier product limit estimate of disease 
free survival in the group that had hepatotoxicity, n=23 and those 
that did not, n=39. 
individual variation in susceptibility to ATO induced 
toxicity, which is probably related to differences in in-
vivo biotransformation of arsenic. This in turn could be 
a result of age, nutritional status, co-morbid conditions, 
environmental factors and genetic polymorphisms.20 In 
addition to a poorly characterized arsenic 
methyltransferase, a number of other enzyme systems 
and polymorphisms have been shown to have an effect 
on arsenic methylation.20,21 Of these, polymorphism in 
the methylene tetra-hydrofolate reductase (MTHFR) 
gene, which results in MTHFR deficiency in 10-20% 
of the Caucasian population, has been reported to be 
associated with increased arsenic related 
neurotoxicity.22 The glutathione S-transferases (GST) 
are a family of proteins that conjugate glutathione 
(GSH) to various electrophiles.23 Chiou et al reported 
that genetic polymorphisms of GST M1 and GST T1 
altered the methylation of arsenic.24 GST’s catalyze the 
GSH dependent reduction of hydroperoxides to their 
corresponding alcohols and help prevent propagation 
of free radicals. It is conceivable that genetic 
polymorphisms in these genes could alter the 
biotransformation of ATO, which in turn could have an 
impact on the efficacy and toxicity profile of this drug. 
We had earlier reported that the hepatotoxicity profile 
in a cohort of patients with newly diagnosed APL 
treated at our center with a single agent ATO regimen 
was significantly associated with the homozygous 
mutant of MTHFR 1298 (C/C) (RR=8.75, p=0.004) 
and there was a trend towards an increased risk of 
hepatotoxicity associated with the GST M1 null 
genotype (RR=3.28, p=0.06).17 We had hypothesized 
then that alteration in biotransformation possibly leads 
to quantitative and qualitative differences in the 
methylated intermediaries that are generated; these 
differences could have a bearing on the efficacy and 
toxicity profile of ATO. A recent study, in part, 
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validates this hypothesis by suggesting that 
dimethylarsinous acid is more toxic than inorganic 
ATO and monomethylyarsinic acid,25 these are some of 
the methylated intermediaries produced in-vivo in 
humans and animals. It is potentially possible to 
consider in future the use of pure or combination of 
methylated ATO derivatives with optimal therapeutic 
and toxicity profiles. 
Clinical Experience with the Use Of Single Agent 
Arsenic Trioxide in Acute Promyelocytic Leukemia. 
The earliest clinical data available on the use of arsenic 
trioxide in the treatment of acute promyelocytic 
leukemia is from two publications from  China.26,27 In 
these studies the complete hematological remission rate 
(CR) achieved varied from 65.6% to 84% and long 
term survival (>10 years) was seen in 9/32 patients in 
one of these studies.11 Majority of the early trials 
involved relapsed cases of APL. There is limited data 
on the use of this as a single agent in the management 
of newly diagnosed cases of APL. Even when used as a 
single agent for induction chemotherapy the 
subsequent consolidation therapy varies making 
comparisons between the published data difficult to 
interpret. 
Our early experience with ATO consisted of two 
patients who were treated in the early 1990’s with what 
was then considered standard of care regimens, one 
with ATRA and one without. Both these patients 
relapsed and were sent on palliative care considering 
the therapeutic options were limited, that the options 
were associated with poor clinical outcome and that 
they were very expensive. These patients subsequently 
took treatment from an ayurvedic (indigenous Indian 
medicine) practitioner and went into durable 
remissions. We were aware that the agent used by the 
practitioner contained ATO. We were however, not 
sure of the dose used. The therapeutic ayurvedic mix 
was administered continuously in these cases and for 
more than 5 years in one case. One of these patients 
developed severe arsenic keratosis and died of a 
secondary squamous epithelial carcinoma.28
It was only after the publication in 1997 by Shen et 
al that we had a sense of the dose of pure ATO that 
could be used in humans.11 In 1998, we initiated a 
study using single agent ATO to treat APL, with 
intravenous ATO being manufactured in house in our 
hospital pharmacy (the basic cost without overheads 
per 10mg vial was Indian Rupees 20 or approximately 
US 50 cents), with appropriate quality control 
measures. Due to legal related issues we transferred 
this manufacturing process to the industry in 2001 
(INTAS pharmaceuticals Ltd, Matoda, Gujarat, India). 
Our observation was that there was no significant 
difference with the agent prepared by us or that 
subsequently manufactured by industry in terms of 
infusion related toxicity or efficacy (unpublished data).      
From January 1998 to December 2004, 72 newly 
diagnosed cases of APL were treated with a regimen of 
single agent ATO at our center. The details of the 
regimen were as previously reported.15,16 Overall 62 
(86.1%) achieved a hematological remission (CR). A 
total of 13 patients relapsed. At a median follow up 60 
months, the 5 year Kaplan-Meier estimate of EFS, DFS 
and OS was 69±5.5%, 80±5.2% and 74.2±5.2% 
respectively (Figure 2). This data has since been 
validated by a subsequent multi-center trial in India 
involving 7 centers across the country (unpublished 
data to be presented at ASH 2011). The data from other 
major studies using either single agent ATO or a ATO 
as a major component in front line therapy18,19,29-31 is 
summarized in table 2.
Table 2: Summary of studies using arsenic trioxide in front line 
therapy in the treatment of APL.
N CR EFS/DFS
Mathews et al.15 72 86%
5 year EFS 69%
5 year OS 74%
Ghavamzadeh et 
al.18
197 86%
5 year OS 64%
5 year DFS 67%
Hu et al.31
85 94%
5 year EFS 89%
(+ATRA*+chemo) 5 year OS 92%
Ravandi et al.29
82 91% 3 year OS 85%
(+ATRA, +GO#) 
Niu et al.37 11 73% 1 year OS 73%
Powell et al.70
244 NA@ 3 year EFS 80%
(RCT$ ATO post 
induction)
3 year OS 86%
Gore et al.30
45 NA 3 year EFS 76%
(ATO post induction) 3 year OS 88%
* ATRA  – all-trans retinoic acid. # GO – gemtuzumab. @ NA  –
not applicable. $ RCT  – randomized controlled trial. 
Toxicity Profile of Arsenic Trioxide. the Theoretical 
Hysteria Versus the Actual Reality! The toxicity 
profile in the initial series reported by us was mild, in 
the majority.16 Significantly, there were no infusion 
related toxicities, alopecia or evidence of exacerbation 
of coagulopathy. Post induction, almost all patients for 
the rest of the duration of treatment had ECOG 
performance scores of 0 or 1. The non hematological 
toxicities, as reported earlier,16 in the majority were 
mild, frequently reverted on continuing ATO and in the 
rest were reversible on discontinuing the drug for an 
interval of 1 – 2 weeks.16 As reported previously 5 
(6.9%) cases developed a differentiation syndrome 
which resolved in 4 and was fatal in one. There were 
Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 2. Five year Kaplan-Meier product limit estimate of (A) Overall survival of (n=72) (B) Event free survival (n=72).
no sudden deaths attributable to a cardiac event in this 
series of patients and on long term follow up there 
were no cases with clinical cardiac dysfunction. There 
were no documented second malignancies documented 
in this cohort.15 Post remission induction, this regimen, 
was administered on an out patient basis. With the 
exception of some early reports of increased hepatic 
and cardiac toxicity32-35 the majority of subsequent 
reports using ATO in newly diagnosed cases is similar 
to our experience.18,19,29-31
There have been periodical major concerns raised 
about the administration of ATO. Very early there was 
a concern about cardiac arrhythmia related sudden 
deaths in patients with APL who were treated with 
ATO. Almost all these deaths happened in induction in 
previously heavily treated patients.32-34 There have 
been no such deaths reported when ATO was used for 
treating a number of other malignancies, albeit stable 
patients. Similarly, it does not appear when 
administered to patients with APL who are in 
remission (none reported in the literature).  The role of 
QTc interval prolongation and limitations of the 
corrected QTc interval value generated with 
tachycardia due to any cause such as infection have 
been reviewed previously and it increasingly 
recognized and accepted that QTc prolongation is an 
electrocardiographic phenomenon with little clinical 
significance in the majority of patients.36 This does not 
mean we should not monitor it or ignore it, though 
response should be judicious and clinically appropriate. 
It has been reported that in more than 2900 cases 
treated by US-FDA approved ATO there have been no 
arrhythmia related deaths.36 We do not believe that 
there is anything sacrosanct or superior about the US-
FDA approved ATO but rather that it in reality it was 
never a significant clinical problem beyond a few case 
reports where the arrythmia’s were probably related to 
other etiologies or at least in part contributed by them.
Next was the suggestion of acute hepatic failure and 
death from hepatoxocity occurred with ATO.37 There 
have been no other major reports since this initial 
publication about 12 years ago. This has definitely not 
been our experience with more than 250 patients 
treated to date at our center (newly diagnosed and 
relapsed). 
There has always been a concern of second
malignancies with the use of ATO. This is based on in-
vitro experiments suggesting oxidative DNA damage38
and clinical observations from cases with long term 
environmental exposure. This theoretical concern is in 
contrast to clinical data available. In early reports of 
investigators from China it was noted that there was no 
increase in second malignancies in patients followed up 
for 10 years.11 A similar observation was made in 
1982, in a cohort of 479 patients who had been treated 
with Fowlers solution [potassium arsenite] for duration 
varying from 2 weeks to 12 years during the period 
1945 – 1969. The median cumulative dose in this 
cohort was 448 mg. It was noted that in this cohort of 
patients there was a marginal increase in fatal and non-
fatal skin cancers but no increase in the incidence of 
internal malignancies.39
A recent report that was meant to highlight the low 
probability of ATO having induced cancers in patients 
(3 cases) receiving oral ATO40 was interpreted in a 
more recent review article as ‘highlights the concern of 
second malignancies’ in patients treated with ATO.41
To the best of our knowledge there are no other (if one 
insists on considering the previous report as second 
cancer to ATO therapy) reported cases of second 
cancers after administration of ATO at currently 
defined therapeutic doses.  It would be reasonable at 
this point, though with limited long term follow up 
data, to state that second cancers following ATO are 
less than that reported following therapy of acute 
myeloid leukemia with currently accepted standard of 
care regimens.  
There have been concerns raised about embryo 
toxicity based on animal models and some data from 
cases with environmental exposure.42 This again is not 
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based on data in humans exposed to currently accepted 
therapeutic doses of ATO, this data for obvious ethical 
reasons is unlikely to be ever generated. However in 
our series, seven of the patients (4 women and 3 men) 
have had 8 normal babies,15 though all happened after 
completion of therapy. In this relatively young cohort 
there were no reports of abortions, fetal abnormalities 
or still births in any couple. While we did not actively 
evaluate fertility there were no reports of couples 
requesting evaluation for sterility.15   
Hair and nail samples from 5 patients of this cohort 
who had completed therapy at least two years earlier 
was compared with that of 5 patients who had just 
completed therapy (not from this cohort)  and 5 healthy 
controls. There was no significant difference in the 
ATO retention in hair and nail samples of controls and 
patients who had completed therapy at least two years 
earlier.15 The median levels, even among the patients 
who had just completed therapy was below the lower 
limit of the normal range described for normal controls 
by the Agency for Toxic Substances and Disease 
Registry (ATSDR based in Atlanta, Georgia, USA 
(http://www.atsdr.cdc.gov/).15        
Pattern and Timing of Haematopoietic Recovery 
Following Treatment with Single Agent Arsenic 
Trioxide. In our initial series the median time to 
achieve CR was 42 days (range: 24-70).16 However, 
this figure does not reflect the entire details of the 
kinetics of leukemia clearance and pattern of normal 
hematopoiesis recovery. As reported initially by us 
about two thirds of patients have a leucocytic response 
after initiation of ATO while in about a third there is 
prolonged leucopenia prior to gradual normalization.43
The leucocytosis can at times be very rapid and 
alarming and based on our early observations we had 
introduced hydroxyurea to control this leucocytosis 
with a recommended sliding scale to adjust the dose 
depending on the WBC count.16 We also noted that this 
was at times not adequate and we allowed use of an 
anthracycline in induction if there was rapid rise in the 
WBC counts after initiation of therapy at pre-defined 
levels and time points.16 In cases that there is 
leucocytic reponse there is often a second leucopenic 
phase (variable duration) and then recovery to normal 
values43 (a triphasic response; Figure 3). Unlike with 
the use of ATRA plus chemotherapy schedules the 
WBC count remains high (in two thirds) or very low 
(in one third), with a low platelet count and significant 
circulating promyelocytes for the first two weeks as 
illustrated in Figure 4. At this time point (around 2 
weeks into therapy) there is often a concern raised, 
among those not familiar with this agent, as to whether 
ATO is doing anything at all to the disease and a 
consideration to change protocol or add on additional 
drugs is discussed. However, if the diagnosis is correct, 
with adequate support during this period and 
continuing ATO, all patients will go on to achieve CR. 
Another common observation in some cases is a 
clinically stable patient in the 4th week of therapy, with 
a normal platelet count but very low WBC count and a 
consideration to stop ATO is made based on the 
argument that the ATO is causing a myelosuppresive 
effect. Our experience would suggest that ATO need 
not be stopped here but can be safely continued for the 
intended duration and one would probably be 
compromising treatment by prematurely stopping 
therapy at this time point.    
Figure 3. Average WBC count among patients with a leucocytic 
response and who achieved complete remission (n=6), illustrating 
the triphasic response.
Pattern of Molecular Response Following Therapy 
with Arsenic Trioxide. It is well recognized that the 
kinetics of leukemia clearance with the use of ATO, in 
induction, is significantly different from that of ATRA 
alone or ATRA plus chemotherapy combinations.44 It 
is not well studied or reported as to what the effects of 
ATO in consolidation and maintenance are on the 
kinetics of relapse. Extrapolation of data generated 
from ATRA plus chemotherapy regimens may 
potentially not be valid when applied to regimens that 
use ATO in upfront therapy. With conventional ATRA 
plus chemotherapy regimens it is well recognized that a 
positive RT-PCR at the end of induction did not have a 
significant prognostic effect while in those who were 
positive post consolidation had an increased risk of 
relapse.41,45 From our own data (unpublished, accepted 
for presentation at ASH 2011) a positive RT-PCR at 
the end of induction was the most significant risk factor 
for subsequent risk of relapse on a multivariate analysis 
(RR=4.9; 95% CI=1.13-21.20; P-value=0.034) and a 
positive RT-PCR at this time point had a sensitivity of 
86.7% and specificity of 42.3% for predicting relapse 
(Figure 5). In this single agent low intensity ATO 
regimen the presence of a positive RT-PCR at the end 
of induction could potentially help identify a subset of 
patients who may benefit from intensification of this 
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Figure 4. The mean WBC and Platelet count ± 1SE over time among patients treated on single agent ATO regimen. A)WBC response 
among those with leucocytosis (n=40). B) WBC response among those without leucocytosis (n=18). C) Platelet count recovery (n=60).
regimen. This strategy remains to be validated in a 
large clinical trial.   
Impact of Additional Cytogenetic and Molecular 
Markers Such as FLT3 Mutations on Clinical 
Response Following Treatment with Arsenic 
Trioxide. The presence of cytogenetic abnormalities at 
diagnosis remains an important prognostic variable in 
patients with newly diagnosed AML.46 Secondary 
cytogenetic changes have been reported to have an 
adverse impact in some subsets of AML, though in 
patients with APL treated with conventional 
chemotherapy a similar adverse effect was not 
reported.47,48 We initially reported a small series of 
newly diagnosed patients with APL treated with single 
agent ATO in which our analysis suggested that there 
was no significant adverse impact of the presence of an 
additional karyotypic abnormality at diagnosis49. 
However, a more recent analysis of our data (larger 
cohort) does suggest that there may be an adverse 
impact of an additional cytogenetic finding at diagnosis 
in newly diagnosed patients though it was not 
significant on a multivariate analysis (unpublished 
data).  
Fms-like tyrosine kinase 3 (FLT3) is a member of 
the class III receptor tyrosine kinase family and is 
expressed on haematopoietic progenitors.50,51
Mutations in the FLT3 receptors have been reported to 
be associated with a poor prognosis in both adult and 
paediatric patients with a diagnosis of acute myeloid 
leukaemia (AML).50 Mutations in the FLT3 receptor 
are commonly seen in patients with APL50. The 
common activating mutations of FLT3 in leukaemia 
include the FLT3 internal tandem duplication (FLT3-
ITD) and a point mutation in the activation loop 
(D835V).50 A recent gene expression profiling study
reported that patients with APL could be segregated 
into those with and without a FLT3-ITD mutation, 
suggesting that these groups were biologically 
different.52  A retrospective analysis of the impact of 
FLT3 mutations in patients with APL, treated with 
conventional ATRA plus chemotherapy regimens, 
reported a higher incidence of induction deaths in one 
study53 while another study reported a trend towards a 
shorter overall survival.54 More recently Chillon et al55
analyzed the Spanish co-operative group data and 
showed that ppatient’s with increased ITD 
mutant/wild-type ratio or longer ITD size displayed 
shorter 5-year relapse-free survival (RFS) (P=0.048 
and P<0.0001, respectively), though patients with 
D835 mutations did not show differences in RFS or 
overall survival (OS). In our series we found that 
FLT3-ITD mutation in 21% and its presence did not 
impact the clinical outcome of patients treated with 
ATO.49 We did however note a longer time to 
molecular remission among those who were FLT3 
mutation positive.49
Figure 5. Event free survival and cumulative incidence of relapse 
based on RT-PCR positivity at the end of induction.
Arsenic Trioxide for the Treatment of Relapsed 
Acute Promyelocytic Leukemia. Patients who relapse 
following an ATRA based chemotherapy schedule can 
achieve a second CR in 60 – 95% of cases with 
chemotherapy though the toxicity with such a regimen 
in this population approaches that seen with high dose 
chemotherapy for acute myeloid leukemia.36 There is a 
high incidence of ATRA resistance in this population 
especially if the relapse occurred within a year of 
completing an ATRA based chemotherapy schedule. In 
this setting ATO is extremely effective in inducing 
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molecular remissions in the majority of patients 
without the toxicity profile of combination 
chemotherapy and does not have cross resistance with 
ATRA.36 This is the only indication for which it is 
approved by the United States Food & Drug 
Administration (FDA). Achieving molecular remission 
prior to a consolidation with an autologous stem cell 
transplant, the preferred option in this setting, has a 
significant bearing on long term outcome. Use of single 
agent ATO as consolidation therapy after achieving 
molecular remission was less effective in this 
population with a 2 year OS of 41% in one series36 and 
an EFS of 33% in a second.37 In our own series we 
reported a significantly better clinical outcome in 
patients who were consolidated with an autologous 
SCT versus those consolidated with ATO or 
ATO+ATRA following treatment of a frank 
hematological relapse of APL.56 Based on the available 
data it would be reasonable in patients with a 
hematological relapse to induce molecular remission 
with ATO and consolidate with an autologous SCT 
(SCT) in those who achieve molecular remission and 
consider an allogeneic SCT for those who fail to 
achieve a molecular remission. 
Conclusions. While there is no doubt as to the efficacy 
of ATO in the management of APL, its position in the 
algorithm in the treatment of this condition is still 
being defined for newly diagnosed cases. Based on the 
available data, it is clear that as a single agent it is the 
most effective drug in the management of APL. For 
patients who have relapsed following conventional 
ATRA plus chemotherapy regimens it is the 
established agent of choice to induce a second 
molecular remission. Preliminary concerns of fatal 
toxicity profile appear to be related more to the 
associated co-morbid conditions than the drug itself, as 
noted by their absence when used in patients with 
newly diagnosed APL without co-morbid conditions 
and in other malignant conditions. On going concerns 
that are frequently voiced about potential long term 
toxicity are not based on significant data. Better 
understanding of its in-vivo biotransformation and 
effect of the different methylated derivatives that are 
generated in this process, could potentially help further 
reduce its toxicity profile while enhancing its efficacy. 
This could be achieved by better ability to predict 
toxicity or efficacy based on genetic polymorphisms 
that have an impact on biotransformation pathways or 
by the use of specific methylated derivatives for 
therapy rather than the native compound which further 
research may potentially demonstrate to have a more 
favorable therapeutic profile. 
In the developing world where the cost of ATO 
(generic) is low, the absence of grade III/IV 
neutropenia and mucositis along with the ability to 
administer the regimen on an out patients basis post 
remission induction significantly reduces the cost of 
treating this condition in comparison to a standard 
ATRA plus chemotherapy regimen. In summary there 
is sufficient evidence to embrace ATO as an important 
drug in the armamentarium for the treatment of APL, 
the optimal mode, combination and schedule for 
utilization of this agent in newly diagnosed cases 
remains to be defined. 
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